Nakagawa-Toyama Yumiko, Hirano Ken-ichi, Tsujii Ken-ichi, Nishida Makoto, Miyagawa Jun-ichiro, Sakai Naohiko, Yamashita Shizuya
Department of Internal Medicine and Molecular Science, Graduate School of Medicine, B5, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
Atherosclerosis. 2005 Nov;183(1):75-83. doi: 10.1016/j.atherosclerosis.2005.02.035. Epub 2005 Jun 20.
The reverse cholesterol transport (RCT) is one of the major protective systems against atherosclerosis, in which high-density lipoprotein (HDL) removes cholesterol from lipid-laden cells and delivers it to the liver. Scavenger receptor class B type I (SR-BI) is a HDL receptor in the liver and adrenal glands and is involved in the selective uptake of cholesteryl ester from HDL, which has been extensively, analyzed using rodent models. However, the expression and regulation of the human homologue of this receptor are not known yet. We previously reported that this receptor is expressed in in vitro differentiated macrophages and its expression is up-regulated by the addition of modified lipoproteins into the medium [Hirano K, Yamashita S, Nakagawa Y, et al. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res 1999;85:108-16]. In order to further investigate the physiological significance of this receptor in humans, we have performed extensive immunohistochemical analyses with specimens of the liver and adrenal glands as well as arteries with different stages of atherosclerotic lesions. In human liver and adrenal glands, a positive SR-BI immunoreactivity was detected in both hepatic and adrenal parenchymal cells as well as Kupffer cells. These parenchymal cells had a strong signal on the cell surface, whereas Kupffer cells showed a heterogeneous and punctate pattern. In human aorta and coronary arteries, SR-BI was highly expressed in atherosclerotic plaques, but not in non-atherosclerotic lesions. Double immunostaining revealed that SR-BI was expressed in a subpopulation of macrophages, of which staining pattern was similar to that observed in Kupffer cells. These data clearly demonstrated that SR-BI was expressed with cell-specific fashions in both the initial and terminal step of RCT in humans. Thus, SR-BI might be physiologically relevant and have distinct tissue-specific functions.
逆向胆固醇转运(RCT)是对抗动脉粥样硬化的主要保护系统之一,其中高密度脂蛋白(HDL)从富含脂质的细胞中清除胆固醇并将其输送到肝脏。I型清道夫受体B类(SR-BI)是肝脏和肾上腺中的一种HDL受体,参与从HDL中选择性摄取胆固醇酯,这已在啮齿动物模型中进行了广泛分析。然而,该受体的人类同源物的表达和调控尚不清楚。我们先前报道,该受体在体外分化的巨噬细胞中表达,并且通过向培养基中添加修饰的脂蛋白可上调其表达[Hirano K,Yamashita S,Nakagawa Y等。人I型清道夫受体B类在培养的人单核细胞衍生巨噬细胞和动脉粥样硬化病变中的表达。Circ Res 1999;85:108 - 16]。为了进一步研究该受体在人类中的生理意义,我们对肝脏、肾上腺以及不同动脉粥样硬化病变阶段的动脉标本进行了广泛的免疫组织化学分析。在人类肝脏和肾上腺中,在肝实质细胞、肾上腺实质细胞以及库普弗细胞中均检测到SR-BI免疫反应阳性。这些实质细胞在细胞表面有强烈信号,而库普弗细胞呈现异质性和点状模式。在人类主动脉和冠状动脉中,SR-BI在动脉粥样硬化斑块中高表达,但在非动脉粥样硬化病变中不表达。双重免疫染色显示,SR-BI在巨噬细胞亚群中表达,其染色模式与在库普弗细胞中观察到的相似。这些数据清楚地表明,SR-BI在人类RCT的起始和终末步骤中均以细胞特异性方式表达。因此,SR-BI可能具有生理相关性并具有独特的组织特异性功能。